PE20080557A1 - Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato - Google Patents

Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato

Info

Publication number
PE20080557A1
PE20080557A1 PE2007000932A PE2007000932A PE20080557A1 PE 20080557 A1 PE20080557 A1 PE 20080557A1 PE 2007000932 A PE2007000932 A PE 2007000932A PE 2007000932 A PE2007000932 A PE 2007000932A PE 20080557 A1 PE20080557 A1 PE 20080557A1
Authority
PE
Peru
Prior art keywords
methyl
halogen
alkyl
azabenzimidazolyl
compounds
Prior art date
Application number
PE2007000932A
Other languages
English (en)
Inventor
Ivan Viktorovich Efremov
Bruce Nelsen Rogers
Allen Jacob Duplantier
Lei Zhang
Qian Zhang
Noha Serour Maklad
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20080557A1 publication Critical patent/PE20080557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN DERIVADO DE AZABENCIMIDAZOLILO DE FORMULA (I), DONDE X3 ES CR6; X2 ES CR4; X8 ES CR3; R1, R2, R3, R4 Y R6 SON H, HALOGENO, CN, ALQUILO, ENTRE OTROS; X1 ES CR7; b ES 0, 1 0 2; b1 ES 1 O 2; R5, R8 Y R9 SON HALOGENO, CIANO, R401, ENTRE OTROS; R7 ES H, HALOGENO, CIANO, ENTRE OTROS; R18 ES H, HALOGENO O ALQUILO; R19 ES H O R8 Y R19 JUNTOS PUEDEN FORMAR =O; R401 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; R17 ES ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS; X4 ES N O CR11; X9 ES N O CR12; X5 ES N O CR13; X6 ES N O CR14; X4, X5, X6 Y X9 SON N; R11, R12, R13 Y R14 SON HALOGENO, CIANO, R601, ENTRE OTROS; R601 ES H, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-((4-(2-METOXI-4-(TRIFLUOROMETIL)FENIL)PIPERIDIN-1-IL)METIL)-1-METIL-1H--IMIDAZO[4,5-b]PIRIDINA, 2-((CIS-4-(4-CLORO-2-FLUOROFENIL)-3-METILPIPERIDIN-1-IL)METIL)-1-METIL-1H-IMIDAZO[4,5-b]PIRIDINA, 2-((CIS-4-(2-FLUORO-4-(TRIFLUOROMETIL)FENIL)-3-METILPIPERIDIN-1-IL)METIL)-1-METIL-1H-IMIDAZO[4,5-c]PIRIDINA, ENTRE OTROS. DICHOS COMPUESTOS ACTUAN SOBRE LOS RECEPTORES DE GLUTAMATO Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS, ICTUS, TRAUMATISMO CRANEAL, DEMENCIA, ENTRE OTROS
PE2007000932A 2006-07-25 2007-07-18 Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato PE20080557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83313606P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
PE20080557A1 true PE20080557A1 (es) 2008-06-29

Family

ID=38780775

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000932A PE20080557A1 (es) 2006-07-25 2007-07-18 Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato

Country Status (7)

Country Link
US (1) US20080312271A1 (es)
AR (1) AR061900A1 (es)
CL (1) CL2007002137A1 (es)
PE (1) PE20080557A1 (es)
TW (1) TW200815431A (es)
UY (1) UY30500A1 (es)
WO (1) WO2008012622A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
WO2008106128A2 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AR067673A1 (es) * 2007-07-26 2009-10-21 Vitae Pharmaceuticals Inc Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
PT2200985E (pt) 2007-09-14 2011-07-21 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
CA2715290A1 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ588954A (en) 2008-05-01 2012-08-31 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CN102119160B (zh) 2008-07-25 2014-11-05 贝林格尔·英格海姆国际有限公司 11β-羟基类固醇脱氢酶1的环状抑制剂
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US20130230459A1 (en) * 2010-11-08 2013-09-05 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGluR2 PET LIGANDS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
MX2016009471A (es) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.
CN104402880A (zh) * 2014-11-02 2015-03-11 湖南华腾制药有限公司 一种咪唑并吡啶衍生物的制备方法
CN107176952A (zh) * 2016-03-09 2017-09-19 湖南华腾制药有限公司 一种咪唑类衍生物的合成方法
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
US20210246140A1 (en) * 2020-01-31 2021-08-12 The General Hospital Corporation Modulators of metabotropic glutamate receptor 2
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020271A1 (en) * 2001-08-29 2003-03-13 Viropharma Incorporated Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
WO2006014918A2 (en) * 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Also Published As

Publication number Publication date
CL2007002137A1 (es) 2008-03-07
US20080312271A1 (en) 2008-12-18
TW200815431A (en) 2008-04-01
UY30500A1 (es) 2008-02-29
WO2008012622A2 (en) 2008-01-31
AR061900A1 (es) 2008-10-01
WO2008012622A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
PE20080557A1 (es) Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR035548A1 (es) Compuestos organicos
PE20121148A1 (es) Compuestos heterociclicos y usos de los mismos
PE20091175A1 (es) Derivados bis-(sulfonilamino) en terapia 205
ATE302775T1 (de) Carbolinderivate
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
AR054799A1 (es) Derivados de oxindol
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
AR080496A1 (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
DE60123420D1 (de) Cyclohexylderivate und ihre anwendung als therapeutische mittel
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
EA199900693A1 (ru) Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a

Legal Events

Date Code Title Description
FD Application declared void or lapsed